Current strategies with eptifibatide and other antiplatelet agents in percutaneous coronary intervention and acute coronary syndromes

Expert Opinion on Drug Metabolism and Toxicology

Volumn 1, Issue 4, 2005, Pages 727-737

  Jennings, Lisa K ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

abciximab; anticoagulation; antiplatelet; eptifibatide; glycoprotein IIb IIIa inhibitors; tirofiban

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; PEPTIDE; TIROFIBAN; TYROSINE;

CORONARY ARTERY DISEASE; DRUG ANTAGONISM; HUMAN; REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; ASPIRIN; CORONARY DISEASE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; TYROSINE;

EID: 33747106641     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.1.4.727     Document Type: Article

References (61)

1. VANE JR, BOTTING RM: The mechanism of action of aspirin. Thromb. Res. (2003) 110(5-6):255-258. (Pubitemid 37329821)
2. THEROUX P, OUIMET H, MCCANS J et al.: Aspirin, heparin or both to treat acute unstable angina. N. Engl. J. Med. (1988) 319:1105-1111.
3. RESEARCH GROUP ON INSTABILITY IN CORONARY ARTERY DISEASE IN SOUTHEAST SWEDEN (RISC): Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk of myocardial infarction, occurrence of severe angina and the need for revascularisation. J. Am. Coll. Cardiol. (1991) 18:1587-1593.
4. LEON MB, BAIM DS, POPMA JJ et al.; for the STENT ANTICOAGULATION RESTENOSIS STUDY INVESTIGATORS: A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N. Engl. J. Med. (1998) 339(23):1665-1671. (Pubitemid 28550691)
5. ANTIPLATELET TRIALISTS COLLABORATION: Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br. Med. J. (1994) 308:81-106.
6. LAU WC, GURBEL PA, WATKINS PB et al.: Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation. (2004): 109:166-171. (Pubitemid 38114134)
7. PETERS RJ, MEHTA SR, FOX KA et al.; for the CURE STUDY INVESTIGATORS: Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation. (2003) 108(14):1682-1687. (Pubitemid 37243654)
8. COUKELL AJ, MARKHAM A: Clopidogrel. Drugs (1997) 54(5):745-750.
9. GEIGER J, BIRCH J, HONIG-LIEDL P et al.: Specific impairment of human platelet P2YAC ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioscler. Thromb. Vasc. Biol. (1999) 19:2007-2011. (Pubitemid 29379936)
10. SAVCIC M, HAUERT J, BACHMANN F et al.: Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin. Thromb. Hemost. (1999) 25(Suppl. 2):15-19. (Pubitemid 29350286)
11. YUSUF S, ZHAO F, MEHTA SR et al.: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. (2001) 345(7):494-502. (Pubitemid 32758501)
12. SCHOMIG A, SCHMITT C, DIBRA A et al.: One year outcomes with abciximab versus placebo during percutaneous coronary intervention after pre-treatment with clopidogrel. Eur. Heart J. (2005) 26(14):1379-1384. (Pubitemid 41373514)
13. MEHILLI J, KASTRATI A, SCHUHLEN H et al.: Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation (2004) 110(24):3627-3635. (Pubitemid 40003783)
14. CAPRIE STEERING COMMITTEE: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet (1996) 348(9038):1329-1339.
15. CHU MW, WILSON SR, NOVICK RJ et al.: Does clopidogrel increase blood loss following coronary artery bypass surgery? Ann. Thorac. Surg. (2004) 78(5):1536-1541. (Pubitemid 39423508)
16. NGUYEN TA, DIODATI JG, PHARAND C: Resistance to clopidogrel: a review of the evidence. J. Am. Coll. Cardiol. (2005) 45(8):1157-1164. (Pubitemid 40523131)
17. GURBEL PA, BLIDEN KP, HIATT BL et al.: Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation (2003) 107(23):2908-2913. (Pubitemid 36736631)
18. JNEID H, BHATT DL, CORTI R et al.: Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study. Arch. Intern. Med. (2003) 163(10):1145-1153. (Pubitemid 36613066)
19. MOBLEY JE, BRESEE SJ, WORTHAM DC et al.: Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization. Am. J. Cardiol. (2004) 93(4):456-458. (Pubitemid 38221356)
20. MATETZKY S, SHENKMAN B, GUETTA V et al.: Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation (2004) 109(25):3171-3175.
21. HANKEY GJ, SUDLOW CL, DUNBABIN DW: Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials. Stroke (2000) 31(7):1779-1784. (Pubitemid 30437537)
22. PHILLIPS DR, CHARO IF, PARISE LV et al.: The platelet membrane glycoprotein IIb-IIIa complex. Blood (1988) 71(4):831-843.
23. WAGNER CL, MASCELLI MA, NEBLOCK DS et al. Analysis of G PIIb/ IIIa receptor number by quantification of 7E3 binding to human platelets. Blood (1996) 88:9907-9914.
24. BATES ER: Clinical trial results with hirudin and bivalirudin for acute coronary artery syndromes. Semin. Thromb. Hemost. (1997) 23(6):575-581. (Pubitemid 28114057)
25. KLEIMAN NS, KLEM J, FERNANDES LS et al.: Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide. Am. Heart. J. (2002) 143(4):585-593. (Pubitemid 34454690)
26. IMPACT-II INVESTIGATORS: Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet (1997) 349(9063):1422-1428.
27. PRISM-PLUS INVESTIGATORS: Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N. Engl. J. Med. (1998) 338(21):1488-1497.
28. RESTORE INVESTIGATORS: Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation (1997) 96(5):1445-1453.
29. CAPTURE INVESTIGATORS: Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet (1997) 349(9063):1429-1435.
30. EPIC INVESTIGATORS: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N. Engl. J. Med. (1994) 330(14):956-961.
31. EPILOG INVESTIGATORS: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N. Engl. J. Med. (1997) 336(24):1689-1696.
32. ESPRIT INVESTIGATORS: Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet (2000) 356(9247):2037-2044.
33. KASTRATI A, MEHILLI J, SCHUHLEN H et al.: A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N. Engl. J. Med. (2004) 350:232-238. (Pubitemid 38071801)
34. DALBY M, MONTALESCOT G, BAL DIT SOLLIER C et al.: Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study. J. Am. Coll. Cardiol. (2004) 43(2):162-168. (Pubitemid 38201138)
35. GURBEL PA, BLIDEN KP, ZAMAN KA et al.: Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the clopidogrel loading with eptifibatide to arrest the reactivity of platelets (CLEAR PLATELETS) study. Circulation (2005) 111:1153-1159. (Pubitemid 40365477)
36. BRENER SJ, ELLIS SG, SCHNEIDER J et al.: Frequency and long-term impact of myonecrosis after coronary stenting. Eur. Heart. J. (2002) 23(11):869-876. (Pubitemid 34717422)
37. IOANNIDIS JP, KARVOUNI E, KATRITSIS DG: Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J. Am. Coll. Cardiol. (2003) 42(8):1406-1411. (Pubitemid 37267281)
38. SILBER S, ALBERTSSON P, AVILES FF et al.: Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur. Heart J. (2005) 26(8):804-847.
39. COLLER BS, SCUDDER LE: Inhibition of dog platelet function by in vivo infusion of F(ab?)2 fragments of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor. Blood (1985) 66(6):1456-1459. (Pubitemid 16194714)
40. IBBOTSON T, MCGAVIN JK, GOA KL: Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation. Drugs (2003) 63(11):1121-1163. (Pubitemid 36700391)
41. SCHROR K, WEBER AA: Comparative pharmacology of GP IIb/IIIa antagonists. J. Thromb. Thrombolysis (2003) 15(2):71-80. (Pubitemid 37498175)
42. EPISTENT INVESTIGATORS: Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet (1998) 352(9122):87-92.
43. PRISM INVESTIGATORS: A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N. Engl. J. Med. (1998) 338(21):1498-1505.
44. TOPOL EJ, MOLITERNO DJ, HERRMANN HC et al.: Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N. Engl. J. Med. (2001) 344(25):1888-1894. (Pubitemid 32553357)
45. ROFFI M, MOLITERNO DJ, MEIER B et al.: Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year followup. Circulation (2002) 105(23):2730-2736. (Pubitemid 34615143)
46. GRETLER DD, GUERCIOLINI R, WILLIAMS PJ: Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function. Clin. Ther. (2004) 26(3):390-398. (Pubitemid 38460967)
47. OSHEA JC, BULLER CE, CANTOR WJ et al.: Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA (2002) 287(5):618-621. (Pubitemid 34252014)
48. PURSUIT INVESTIGATORS: Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. N. Engl. J. Med. (1998) 339(7):436-443.
49. LINCOFF AM, BITTL JA, HARRINGTON RA et al.: Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA (2003) 289(7):853-863. (Pubitemid 37430344)
50. BATCHELOR WB, TOLLESON TR, HUANG Y et al.: Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of platelet aggregation with aggrastat, ReoPro and eptifibatide. Circulation (2002) 106(12):1470-1476.
51. SAUCEDO JF, GARZA L, WOLFORD DC et al.: Comparative pharmacodynamic evaluation of eptifibatide and tirofiban HCl in patients undergoing percutaneous coronary intervention (the TAM1 Study). Am. J. Cardiol. (2004) 93(10):1279-1282. (Pubitemid 38595684)
52. SAUCEDO JF, LUI HK, GARZA L et al.: Comparative pharmacodynamic evaluation of eptifibatide and abciximab in patients with non-ST-segment elevation acute coronary syndromes: the TAM2 study. J. Thromb. Thrombolysis (2004) 18(2):67-74. (Pubitemid 40485112)
53. KEREIAKES DJ, BRODERICK TM, ROTH EM et al.: Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention. Am. J. Cardiol. (1999) 84(4):391-395. (Pubitemid 29398656)
54. BRAUNWALD E, ANTMAN EM, BEASLEY JW et al.: ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-STsegment elevation myocardial infarctionsummary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). Am. Coll. Cardiol. (2002) 40(7):1366-1374.
55. SMITH SC, DOVE JT, JACOBS AK et al.: ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)-executive summary. J. Am. Coll. Cardiol. (2001) 37(8):2215-2238. (Pubitemid 32548014)
56. STEINHUBL SR, TALLEY JD, BRADEN GA et al.: Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Integra) multimember study. Circulation (2001) 103:2572-2578. (Pubitemid 32521967)
57. HEESCHEN C, DIMMELER S, HAMM CW et al.; for the CAPTURE STUDY INVESTIGATORS: Soluble CD40 Ligand in acute coronary syndromes. N. Engl. J. Med. (2003) 348:1104-1111. (Pubitemid 36337321)
58. WELT FG, ROGERS SD, ZHANG X et al.: GP IIb/IIIa inhibition with eptifibatide lowers levels of soluble CD40L and RANTES after percutaneous coronary intervention. Catheter. Cardiovascular. Intern. (2004) 61(2):185-189. (Pubitemid 38160615)
59. RIOUFOL G, FINET G, GINON I et al.: Multiple atherosclerotic plaque rupture in acute coronary syndrome: a three-vessel intravascular ultrasound study. Circulation (2002) 106(7):804-808.
60. AULT KA, CANNON CP, MITCHELL J et al.: Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in myocardial infarction. J. Am. Coll. Cardiol. (1999) 33:634-639.
61. TRIP MD, CATS VM, VAN CAPELLE FJ et al.: Platelet hyper reactivity and prognosis in survivors of myocardial infarction. N. Engl. J. Med. (1990) 322:1549-1554. (Pubitemid 20176694)